Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematuria induced by urethral catheterization.

R S Hockberger, B Schwartz, J Connor

    Annals of Emergency Medicine
    |May 1, 1987
    PubMed
    Summary

    Urethral catheterization rarely causes significant traumatic hematuria. In a study of 93 emergency department patients, only 17.2% experienced hematuria, and it was mild when present.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.

    Gynecologic oncology·2006
    Same author

    Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

    European journal of cancer (Oxford, England : 1990)·2006
    Same author

    How often should a port-A-cath be flushed?

    Cancer investigation·2005
    Same author

    An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.

    Investigational new drugs·2005
    Same author

    HTS magnetometers for fetal magnetocardiography.

    Neurology & clinical neurophysiology : NCN·2005
    Same author

    Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

    Annals of oncology : official journal of the European Society for Medical Oncology·2005

    Area of Science:

    • Urology
    • Emergency Medicine
    • Medical Diagnostics

    Background:

    • Urethral catheterization is a common medical procedure.
    • Traumatic hematuria is a potential complication.
    • Understanding the incidence and severity of catheter-induced hematuria is important for patient care.

    Purpose of the Study:

    • To quantify the incidence of traumatic hematuria following urethral catheterization.
    • To assess the severity of hematuria induced by catheterization.

    Main Methods:

    • Prospective study comparing pre- and post-catheterization urinalyses.
    • Included 93 emergency department patients with acute abdominal complaints.
    • Data collected on patient demographics and catheterization provider.

    Main Results:

    • Overall, 16 of 93 patients (17.2%) developed hematuria post-catheterization.
    • When present, hematuria was consistently mild, not exceeding 3 red blood cells per high-power field (RBC/hpf).
    • Catheterizations were performed by nurses, resident house-staff, and nurse practitioners.

    Conclusions:

    • Urethral catheterization in this patient cohort resulted in a low incidence of hematuria.
    • The induced hematuria was generally mild and not clinically significant.
    • These findings support the safety of urethral catheterization regarding hematuria complications.

    Related Experiment Videos